According to a recent Lex Machina report, the number of Abbreviated New Drug Application (ANDA) patent litigation filings increased 68% from 2014-2015. In the five years prior, an average of 269 cases were filed each year, but from 2014-2015, the average rose to 451 cases. In the report, Finnegan is cited as one of the top firms filing ANDA lawsuits on behalf of plaintiffs with 274 cases. While ANDA cases only make up approximately 10 percent of all patent filings, this increase is a sign that things are becoming intense in the pharmaceutical industry.